PE20181330A1 - Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer - Google Patents
Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancerInfo
- Publication number
- PE20181330A1 PE20181330A1 PE2018001267A PE2018001267A PE20181330A1 PE 20181330 A1 PE20181330 A1 PE 20181330A1 PE 2018001267 A PE2018001267 A PE 2018001267A PE 2018001267 A PE2018001267 A PE 2018001267A PE 20181330 A1 PE20181330 A1 PE 20181330A1
- Authority
- PE
- Peru
- Prior art keywords
- sting
- cancer
- activity
- stimulator
- conditions associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277273P | 2016-01-11 | 2016-01-11 | |
| US201662436759P | 2016-12-20 | 2016-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181330A1 true PE20181330A1 (es) | 2018-08-20 |
Family
ID=58010371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001267A PE20181330A1 (es) | 2016-01-11 | 2017-01-11 | Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10604542B2 (OSRAM) |
| EP (1) | EP3402801B1 (OSRAM) |
| JP (1) | JP6867395B2 (OSRAM) |
| KR (2) | KR102789862B1 (OSRAM) |
| CN (1) | CN109451740B (OSRAM) |
| AU (1) | AU2017207757B2 (OSRAM) |
| BR (1) | BR112018013808A2 (OSRAM) |
| CA (1) | CA3011528A1 (OSRAM) |
| CL (1) | CL2018001870A1 (OSRAM) |
| CO (1) | CO2018008196A2 (OSRAM) |
| DK (1) | DK3402801T3 (OSRAM) |
| EA (1) | EA036421B1 (OSRAM) |
| ES (1) | ES3046957T3 (OSRAM) |
| FI (1) | FI3402801T3 (OSRAM) |
| HR (1) | HRP20251050T1 (OSRAM) |
| IL (1) | IL260427B (OSRAM) |
| LT (1) | LT3402801T (OSRAM) |
| MX (1) | MX2018008266A (OSRAM) |
| MY (1) | MY194058A (OSRAM) |
| PE (1) | PE20181330A1 (OSRAM) |
| PL (1) | PL3402801T3 (OSRAM) |
| PT (1) | PT3402801T (OSRAM) |
| RS (1) | RS67188B1 (OSRAM) |
| SG (1) | SG11201805888SA (OSRAM) |
| SI (1) | SI3402801T1 (OSRAM) |
| SM (1) | SMT202500412T1 (OSRAM) |
| WO (1) | WO2017123669A1 (OSRAM) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20171448A1 (es) | 2015-03-10 | 2017-10-02 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
| HRP20251050T1 (hr) * | 2016-01-11 | 2025-11-07 | Innate Tumor Immunity, Inc. | Ciklični dinukleotidi za liječenje stanja povezanih s aktivnošću sting kao što je rak |
| CN114751950B (zh) | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| MX392605B (es) | 2016-07-06 | 2025-03-11 | Invox Pharma Ltd | Compuestos, composiciones y metodos para el tratamiento de enfermedades. |
| FI3506884T4 (fi) | 2016-08-30 | 2024-12-23 | Dana Farber Cancer Inst Inc | Lääkkeenantokoostumuksia ja niiden käyttötapoja |
| GEP20217285B (en) | 2016-10-04 | 2021-08-10 | Merck Sharp & Dohme | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| CA3058134A1 (en) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| US11259980B2 (en) | 2017-07-31 | 2022-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Soft inflatable exosuit for knee rehabilitation |
| JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ |
| US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
| KR102782200B1 (ko) | 2017-08-30 | 2025-03-17 | 에이제이 사이언시즈 (이씽) 코., 엘티디 | 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드 |
| KR102812783B1 (ko) * | 2017-08-31 | 2025-05-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11180524B2 (en) | 2017-09-14 | 2021-11-23 | Janssen Biopharma, Inc. | Modified nucleoside phosphoramidites |
| JP7212683B2 (ja) * | 2017-10-10 | 2023-01-25 | ブリストル－マイヤーズ スクイブ カンパニー | 抗がん剤としての環状ジヌクレオチド |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| KR20200098511A (ko) | 2017-11-10 | 2020-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Sting 조절제 화합물, 및 제조 및 사용 방법 |
| US11685761B2 (en) | 2017-12-20 | 2023-06-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| EP3505527A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
| US10519187B2 (en) * | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| JP7250808B2 (ja) * | 2018-03-08 | 2023-04-03 | ブリストル－マイヤーズ スクイブ カンパニー | 抗がん剤としての環状ジヌクレオチド |
| US20210015915A1 (en) | 2018-03-23 | 2021-01-21 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| JP7326319B2 (ja) | 2018-04-03 | 2023-08-15 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物 |
| EP3774765A4 (en) | 2018-04-03 | 2021-12-29 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| ES2929415T3 (es) | 2018-05-25 | 2022-11-29 | Incyte Corp | Compuestos heterocíclicos tricíclicos como activadores de STING |
| US12291548B2 (en) | 2018-07-10 | 2025-05-06 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| US11691990B2 (en) | 2018-08-16 | 2023-07-04 | Eisai R&D Management Co., Ltd | Salts of compounds and crystals thereof |
| PT3848054T (pt) | 2018-09-06 | 2025-04-03 | Daiichi Sankyo Co Ltd | Conjugados anticorpo-fármaco de derivados de dinucleótidos cíclicos |
| CA3111784A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Methods and compositions for the treatment of disease with immune stimulatory conjugates |
| WO2020057546A1 (zh) | 2018-09-21 | 2020-03-26 | 上海迪诺医药科技有限公司 | 环状二核苷酸类似物、其药物组合物及应用 |
| US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020089815A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| WO2020117739A1 (en) * | 2018-12-04 | 2020-06-11 | Bristol-Myers Squibb Company | Process for the preparation of a cyclic dinucleotide |
| US12129267B2 (en) | 2019-01-07 | 2024-10-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| US12060384B2 (en) | 2019-02-05 | 2024-08-13 | Bristol-Myers Squibb Company | Synthesis of 1,2,5-tri-o-benzoyl-3-dibenzylamino-3-deoxyribose as intermediate for producing 3′-amino-3′-deoxyadenosine and 3′-amino-3′-deoxyguanosine and the protected derivatives thereof |
| WO2020229982A1 (en) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| EP3993834A1 (en) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| CN114206898B (zh) * | 2019-07-25 | 2024-06-25 | 百济神州有限公司 | 作为sting激动剂的环状二核苷酸 |
| WO2021067644A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| JP7787514B2 (ja) | 2019-12-26 | 2025-12-17 | 国立大学法人東海国立大学機構 | ポリヌクレオチド及び医薬組成物 |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| JPWO2021177438A1 (OSRAM) | 2020-03-06 | 2021-09-10 | ||
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| WO2021216698A1 (en) * | 2020-04-21 | 2021-10-28 | Duke University | Compositions and methods for the treatment of pain |
| CA3178252A1 (en) | 2020-05-11 | 2021-11-18 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
| TW202216211A (zh) | 2020-07-01 | 2022-05-01 | 美商希沃爾拜克治療公司 | 抗asgr1抗體共軛物及其用途 |
| EP4295917A3 (en) | 2020-08-07 | 2024-02-28 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| TW202227479A (zh) | 2020-09-02 | 2022-07-16 | 日商第一三共股份有限公司 | 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶 |
| EP4228657A4 (en) * | 2020-10-15 | 2024-11-20 | The Regents Of The University Of Michigan | Crystalline polymorphic forms of sting agonists associated with metal ions capable of modulating an immune response |
| KR102466750B1 (ko) | 2020-10-23 | 2022-11-15 | 아주대학교산학협력단 | 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| WO2022094262A1 (en) | 2020-10-30 | 2022-05-05 | Avacta Life Sciences Limited | Fap-activated serum extended half-life therapeutic conjugates |
| KR20230106606A (ko) | 2020-11-09 | 2023-07-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 항체 약물 접합체 |
| AU2022302611A1 (en) | 2021-06-30 | 2024-02-15 | Kyowa Kirin Co., Ltd. | Polynucleotide and medicinal composition |
| EP4488378A1 (en) | 2022-03-02 | 2025-01-08 | Daiichi Sankyo Company, Limited | Method for producing fc-containing molecule |
| CN119744182A (zh) | 2022-08-29 | 2025-04-01 | 第一三共株式会社 | 包含突变Fc区的抗体药物偶联物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| NZ537686A (en) | 2002-06-20 | 2007-01-26 | Nippon Suisan Kaisha Ltd | A beta2 agonist prodrug having reduced side effects |
| WO2005089777A1 (en) * | 2004-03-15 | 2005-09-29 | Karaolis David K R | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| CA2873402C (en) * | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| SG11201407875UA (en) | 2012-06-08 | 2014-12-30 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
| AU2013358892B2 (en) * | 2012-12-13 | 2018-06-21 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| CA2908154C (en) * | 2013-04-29 | 2023-11-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| DK2996473T3 (da) | 2013-05-18 | 2019-11-04 | Aduro Biotech Inc | Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering |
| US9642830B2 (en) | 2013-10-21 | 2017-05-09 | Drexel University | Use of sting agonists to treat hepatitis B virus infection |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| WO2015077534A1 (en) | 2013-11-22 | 2015-05-28 | Massachusetts Institute Of Technology | Photovoltaic power balancing and differential power processing |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| CA2950033A1 (en) | 2014-06-04 | 2015-12-10 | Glaxosmithkline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| PL3233882T3 (pl) | 2014-12-16 | 2020-04-30 | Kayla Therapeutics | Fluorowane cykliczne dinukleotydy do indukcji cytokin |
| US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| PE20171448A1 (es) | 2015-03-10 | 2017-10-02 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon |
| MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
| NZ738202A (en) | 2015-12-03 | 2019-07-26 | Glaxosmithkline Ip Dev Ltd | Cyclic purine dinucleotides as modulators of sting |
| HRP20251050T1 (hr) * | 2016-01-11 | 2025-11-07 | Innate Tumor Immunity, Inc. | Ciklični dinukleotidi za liječenje stanja povezanih s aktivnošću sting kao što je rak |
| CN114751950B (zh) | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
-
2017
- 2017-01-11 HR HRP20251050TT patent/HRP20251050T1/hr unknown
- 2017-01-11 ES ES17704338T patent/ES3046957T3/es active Active
- 2017-01-11 PE PE2018001267A patent/PE20181330A1/es unknown
- 2017-01-11 PL PL17704338.7T patent/PL3402801T3/pl unknown
- 2017-01-11 JP JP2018536116A patent/JP6867395B2/ja active Active
- 2017-01-11 EP EP17704338.7A patent/EP3402801B1/en active Active
- 2017-01-11 LT LTEPPCT/US2017/013066T patent/LT3402801T/lt unknown
- 2017-01-11 AU AU2017207757A patent/AU2017207757B2/en active Active
- 2017-01-11 KR KR1020187022863A patent/KR102789862B1/ko active Active
- 2017-01-11 SI SI201731621T patent/SI3402801T1/sl unknown
- 2017-01-11 MX MX2018008266A patent/MX2018008266A/es unknown
- 2017-01-11 CN CN201780015198.2A patent/CN109451740B/zh active Active
- 2017-01-11 RS RS20250892A patent/RS67188B1/sr unknown
- 2017-01-11 SG SG11201805888SA patent/SG11201805888SA/en unknown
- 2017-01-11 MY MYPI2018702369A patent/MY194058A/en unknown
- 2017-01-11 DK DK17704338.7T patent/DK3402801T3/da active
- 2017-01-11 SM SM20250412T patent/SMT202500412T1/it unknown
- 2017-01-11 FI FIEP17704338.7T patent/FI3402801T3/fi active
- 2017-01-11 BR BR112018013808-8A patent/BR112018013808A2/pt active Search and Examination
- 2017-01-11 PT PT177043387T patent/PT3402801T/pt unknown
- 2017-01-11 EA EA201891565A patent/EA036421B1/ru not_active IP Right Cessation
- 2017-01-11 KR KR1020257010190A patent/KR20250049441A/ko active Pending
- 2017-01-11 US US15/748,685 patent/US10604542B2/en active Active
- 2017-01-11 WO PCT/US2017/013066 patent/WO2017123669A1/en not_active Ceased
- 2017-01-11 CA CA3011528A patent/CA3011528A1/en active Pending
-
2018
- 2018-07-04 IL IL260427A patent/IL260427B/en active IP Right Grant
- 2018-07-10 CL CL2018001870A patent/CL2018001870A1/es unknown
- 2018-08-02 CO CONC2018/0008196A patent/CO2018008196A2/es unknown
-
2020
- 2020-01-31 US US16/778,281 patent/US10961270B2/en active Active
-
2021
- 2021-01-28 US US17/160,578 patent/US11505571B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181330A1 (es) | Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer | |
| UY37464A (es) | Métodos para tratar infecciones por el virus filoviridae | |
| SA519401435B1 (ar) | مركبات حلقية ثنائية النيوكليوتيد | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| DOP2016000316A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| CL2019001485A1 (es) | Dinucleótido cíclico como agonistas de sting (estimulador de genes de interferón). | |
| CL2017001932A1 (es) | Dinucleotidos cíclicos útiles para el tratamiento de cancer entre otros. | |
| CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| CO2019004034A2 (es) | Compuesto de piridina | |
| BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MX2016016364A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| UY37360A (es) | Nucleósidos sustituidos, nucleótidos y análogos de estos | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| MX2020004914A (es) | Metodos y composiciones para tratar el cancer mediante la modificacion de multiples brazos del sistema inmunitario. | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| UY37980A (es) | Compuestos novedosos para tratar enfermedades parasitarias | |
| BR112017002629A2 (pt) | decoys de oligonucleotídeo para o tratamento de dor | |
| MX2019008787A (es) | Sal de etano-sulfonato del derivado de quinolina. | |
| MX2019006886A (es) | Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2). | |
| MX2018013885A (es) | Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3). | |
| AR109850A2 (es) | Métodos para tratar infecciones por el virus filoviridae |